Skip to main content

News Releases & Statements

News Releases & Statements

LLS Statement on Federal Vaccination Strategy

(Rye Brook, NY, Sept. 10, 2021) — Our top priority is — and always has been — the safety of blood cancer patients and survivors. We know that they are at increased risk of serious illness and death from COVID-19. However, up to 1 in 4 blood cancer patients won’t produce COVID-19 antibodies after vaccination, making it even more important for those around them to be vaccinated. 

Read More

New Study Shows Most Blood Cancer Patients Benefit from an Additional COVID-19 Vaccine Dose

Immune suppressing treatments-an essential component of many patient's cancer care-can blunt vaccine immune response

Read More

Every 180 Seconds, Someone in the U.S. is Diagnosed with a Blood Cancer; it’s Time to Make an Impact Together

(Rye Brook, NY, Sept. 1, 2021) — September is Blood Cancer Awareness Month, an opportunity to remind the public that every 180 seconds, someone in the U.S. has their life turned upside down by a blood cancer diagnosis. Read More

New COVID-19 Staff Safety Policies at LLS

The following memo from Louis J. DeGennaro, Ph.D., President and Chief Executive Officer of The Leukemia & Lymphoma Society (LLS), was shared with LLS staff on Tuesday, 8/17. The email has been edited to remove internal links.

Read More

FDA APPROVES NEW TREATMENT OPTION FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA

The U.S. Food and Drug Administration (FDA) approved loncastuximab tesirine-lpyl (ZYNLONTA) to treat adult patients with relapsed or refractory (R/R) large B-cell lymphoma  after two or more earlier treatments with systemic therapy including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma.

Read More

LLS Urges Blood Cancer Patients to get Vaccinated as its National Patient Registry Enters Next Phase in COVID-19 Vaccine Studies

Rye Brook, N.Y., July 15, 2021—The Leukemia & Lymphoma Society® (LLS) began recruitment this week for a new study evaluating T-cell immune response to COVID-19 vaccine among people with a current or past diagnosis of blood cancer. This invitation-only follow-up study will include a sub-set of participants from a larger LLS study examining COVID-19 spike antibody response to vaccination. Read More

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org.  An LLS representative will respond as soon as possible.